Last edition
News about "VAV1 degraders "
Monte Rosa Therapeutics Partners with Novartis on Degraders for Immune Diseases
Monte Rosa to receive an upfront payment of USD 120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory and sales milestones, as well as tiered royalties on global net sales.
VAV1 Degraders | 16/09/2025 | By Dineshwori | 203
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members